Relay Therapeutics Raises $400 million Series D
Relay Therapeutics raised $400M in Series D financing led by Various. AI-powered dynamic protein targeting for cancer. The new capital is framed around Advance RLY-2608 PI3K inhibitor through Phase 2 cancer trials.
What it does
AI-powered dynamic protein targeting for cancer. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
Dynamo platform identified 5 clinical candidates in 5 years vs 20 year average. Management framed the new capital around Advance RLY-2608 PI3K inhibitor through Phase 2 cancer trials.
Trend impact
AI targeting disease-relevant protein motion beyond static structure. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- April 1, 2021 · Series D · $400 million · Various
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round